together: “forma-odezhda.ru Affiliate Program - viglink.com” plus 49 more |  |
- forma-odezhda.ru Affiliate Program - viglink.com
- academic2.ru united (RSS) Еще работаем oligodactyly Перевод: с...
- Fredet-Ramstedt operation - Medical dictionary
- https://t.me/enacademicgroup/5355424
- academic2.ru united (RSS) Анимаг ² 10.08.2020 — Анимаг: Анимаг (англ....
- https://t.me/enacademicgroup/5355422
- Lassar paste - Medical dictionary
- http://www.seomastering.com/audit/translate.academic2.ru/
- خلاصة كاملة (RSS) Forma-odezhda.
- Forma-odezhda.ru
- Luminar Jumps After Hiring Executives Away From Tesla and Intel
- @deacademiccom posted a photo httpst.medeacademiccom108590
- Glancy Prongay & Murray LLP Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against Intrusion Inc. (INTZ)
- Уходи
- feedspot (RSS) full digest (RSS) Forma-odezhda.ru (VK) Don't have Telegram yet? Try...
- deacademic.com Goodenough Island 07.06.2020 — Die Goodenough-Insel (von den Insulanern...
- Академика РАН задержала полиция за репост об акции протеста
- academic2.ru united (RSS) Анимаг ² 10.08.2020 — Анимаг: Анимаг (англ....
- forma-odezhda.ru Archive: 21 Tweets - 6,384 Impressions
- Don
- mamma - Medical dictionary
- Enacademic
- Is forma-odezhda.ru Safe? forma-odezhda Reviews & Safety ...
- https://t.me/enacademicgroup/5355438
- [Media]
- (https://clck.
- Vista Realty Partners Names New Regional Partners
- Here's Android 12 Developer Preview 3!
- "Юрка вернулся!" Возвращение Юрия Никулина с фронта. 1946 год
- academic2.ru united (RSS) Еще работаем oligodactyly Перевод: с...
- Cultiva® Enhances Global Leadership Team
- DLA Piper Advises Ekata In Its US$850 Million Acquisition By Mastercard
- Oppenheim sign - Medical dictionary - Enacademic.com
- Statement On Issuance Of Form FDA 483 At Emergent Bayview Facility
- https://t.me/enacademicgroup/5355426
- https://t.me/enacademicgroup/5355430
- http://www.seomastering.com/audit/translate.academic2.ru/
- Deadline Reminder: Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against FibroGen Inc. (FGEN)
- deacademic.com Kultus 01.03.2021 — ist die Bezeichnung für eine Verwaltungsbehörde...
- InventHelp Inventor Develops Child Safety System For Vehicles (ORD-2884)
- .
- https://apescout.com/site/translate.academic2.ru
- Nancy Ludington
- forma-odezhda.ru - searX.Slash-dev.de
- Deadline Reminder: Law Offices Of Howard G. Smith Reminds Investors Of Looming Deadline In The Class Action Lawsuit Against LifeMD, Inc. (LFMD)
- Detected change on https://clck.
- https://t.me/enacademicgroup/5355428
- полный дайджест (RSS) Forma-odezhda.
- (https://clck.ru/PWzqK)together (RSS) Telegram pub (RSS) Detected change on...
- Valve исправила ошибку, из-за которой страдали пользователи Steam более чем с 25 тыс. игр
| forma-odezhda.ru Affiliate Program - viglink.com Posted: 21 Apr 2021 09:48 AM PDT forma-odezhda.ru: Open : About Sovrn //Commerce. By identifying commercial products mentioned within a publisher's content, //Commerce automatically monetizes those terms by transforming them into revenue generating hyperlinks whose destinations are determined in real-time auctions. Our technology works across sites, apps, and social networks ... |
| academic2.ru united (RSS) Еще работаем oligodactyly Перевод: с... Posted: 21 Apr 2021 09:52 AM PDT |
| Fredet-Ramstedt operation - Medical dictionary Posted: 21 Apr 2021 09:39 AM PDT 21.01.2021 — Fre·det Ram·stedt operation (frĕ daґ rahmґshtet) [Pierre Fredet, French surgeon, 1870â€"1946; Conrad Ramstedt, German surgeon, 1867â€"1963] see under ... |
| https://t.me/enacademicgroup/5355424 Posted: 21 Apr 2021 09:37 AM PDT Русский: вместе (RSS) -- Delivered by Feed43 service |
| academic2.ru united (RSS) Анимаг ² 10.08.2020 — Анимаг: Анимаг (англ.... Posted: 21 Apr 2021 09:52 AM PDT |
| https://t.me/enacademicgroup/5355422 Posted: 21 Apr 2021 09:37 AM PDT together (RSS) -- Delivered by Feed43 service |
| Lassar paste - Medical dictionary Posted: 21 Apr 2021 09:44 AM PDT Lassar paste - Medical dictionary https://ift.tt/32xfOkF |
| http://www.seomastering.com/audit/translate.academic2.ru/ Posted: 21 Apr 2021 09:42 AM PDT |
| خلاصة كاملة (RSS) Forma-odezhda. Posted: 21 Apr 2021 09:40 AM PDT العربية: feedspot (RSS) خلاصة كاملة (RSS) Forma-odezhda.ru (VK) Don & amp;#39;t هل لديك برقية حتى الآن ؟ جربه.. https://t.me/enacademic/2282035 feedspot (RSS) خلاصة كاملة (RSS) Forma-odezhda.ru (http://forma-odezhda.ru/) (VK) Don & # 39;t هل لديك برقية حتى الآن ؟ تحاول ذلك الآن& # 33; ... خلاصة كاملة (RSS) Forma-odezhda.ru (http://forma-odezhda.ru/) (VK) لم يكن لديك برقية حتى الآن ؟ نحاول الآن! لم يكن لديك برقية حتى الآن ؟ نحاول الآن! السياق تضمين عرض في القناة نسخ TelegramEnacademic |
| Posted: 21 Apr 2021 09:44 AM PDT Forma-odezhda.ru https://ift.tt/2RSSwDH |
| Luminar Jumps After Hiring Executives Away From Tesla and Intel Posted: 21 Apr 2021 09:52 AM PDT Tesla's former general counsel joined Luminar as chief legal officer, while Intel's VP of investor relations was hired to take the same role at Luminar. Shares of Luminar Technologies (LAZR) - Get Report shares soared Wednesday, after the maker of sensors and software for autonomous vehicles announced it had hired two executives from Tesla (TSLA) - Get Report and Intel (INTC) - Get Report. Alan Prescott joins as chief legal officer, after a stint as general counsel at Tesla. Prior to his four years at Tesla, Prescott led Uber's (UBER) - Get Report Advanced Technology Group's legal team as senior counsel overseeing commercial, regulatory, litigation, privacy and cybersecurity. Luminar also hired Trey Campbell as vice president and leader of its investor relations department. Prior to joining Luminar, he spent 20 years at Intel, beginning as a financial analyst and later serving as vice president of investor relations. Prescott started his career at Ford Motor (F) - Get Report as a safety engineer before receiving his law degree from Georgetown University. He then spent 10 years at Ford leading various legal operations. Luminar recently traded at $19.43, up 18.3%. It has gone up 82% since going public in December, amid widespread enthusiasm for the autonomous vehicle sector. To be sure, however, it has plunged 55% since Dec. 8. Tesla shares were up 0.9% to $725.12, while Intel shares rose 1.0% to $63.33. Last month, Luminar detailed its plans for 2021, including as much as a doubling of revenue from 2020. The Portola Valley, Calif., company estimates 2021 revenue will come in at $25 million to $30 million, compared with around $14 million for 2020. In December, Luminar said its relationship with Intel's Mobileye was moving "full speed ahead." Luminar had taken a hit following news accounts that said Mobileye, which makes self-driving car and advanced driver-assistance systems, planned to develop its own sensors. |
| @deacademiccom posted a photo httpst.medeacademiccom108590 Posted: 21 Apr 2021 09:44 AM PDT @deacademiccom posted a photo https://ift.tt/3vbQ0qe https://ift.tt/3x7V2pP |
| Posted: 21 Apr 2021 09:49 AM PDT Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming June 15, 2021deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Intrusion Inc. ("Intrusion" or the "Company") (INTZ) securities between January 13, 2021 and April 13, 2021, inclusive (the "Class Period"). If you suffered a loss on your Intrusion investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/intrusion-inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights. Intrusion develops, sells, and supports products that purport to protect entities from cyberattacks by combining advanced threat intelligence with real-time artificial intelligence. It offers three products: Shield, a cybersecurity solution packaged as a comprehensive, real-time AI-based Security-as-a-Service; TraceCop, a big data tool with IP intelligence, including reputation information on known good and known bad active IP addresses; and Savant, a network monitoring solution that identifies suspicious traffic in real-time. On April 14, 2021, White Diamond Research published a report alleging, among other things, that Intrusion's product, Shield, "has no patents, certifications, or insurance, which are all essential for selling cybersecurity products" and that "Shield is based on open-source data already available to the public." Thus, the report stated that "Shield is a repackaging of pre-existing technology rather than an innovative offering." Moreover, the report alleged that the claims that Shield "stopp[ed] a total of 77,539,801 cyberthreats from 805,110 uniquely malicious entities . . . in the 90-day beta program" were "outlandish," leading White Diamond to question "[h]ow have these companies been able to function so far, as they've been attacked many times per minute by ransomware, malware, data theft, phishing and DDoS attacks?" On this news, the Company's share price fell $4.50, or over 16%, to close at $23.75 per share on April 14, 2021, on unusually heavy trading volume. The share price continued to decline by $3.22, or 14%, over the next trading session to close at $20.53 per share on April 15, 2021. Throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that Intrusion's Shield product was merely a repackaging of existing technology in the Company's portfolio; (2) that Shield lacked the patents, certifications, and insurance critical to the sale of cybersecurity products; (3) that the Company had overstated the efficacy of Shield's purported ability to protect against cyberattacks; (4) that, as a result of the foregoing, Intrusion's Shield was reasonably unlikely to generate significant revenue; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Follow us for updates on LinkedIn, Twitter, or Facebook. If you purchased or otherwise acquired Intrusion securities during the Class Period, you may move the Court no later than June 15, 2021to request appointment as lead plaintiff in this putative class action lawsuit. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005864/en/ |
| Posted: 21 Apr 2021 10:07 AM PDT |
| feedspot (RSS) full digest (RSS) Forma-odezhda.ru (VK) Don't have Telegram yet? Try... Posted: 21 Apr 2021 09:39 AM PDT |
| deacademic.com Goodenough Island 07.06.2020 — Die Goodenough-Insel (von den Insulanern... Posted: 21 Apr 2021 09:44 AM PDT deacademic.com Goodenough Island 07.06.2020 — Die Goodenough-Insel (von den Insulanern... https://ift.tt/2RIeBof |
| Академика РАН задержала полиция за репост об акции протеста Posted: 21 Apr 2021 10:07 AM PDT https://www.rbc.ru/politics/21/04/2021/60801b1d9a79472a3e60f39f  В Нижнем Новгороде полицейские задержали и доставили в отдел академика РАН, заместителя директора Института прикладной физики Ефима Хазанова. Написал EasyLiving на shapito.d3.ru / комментировать |
| academic2.ru united (RSS) Анимаг ² 10.08.2020 — Анимаг: Анимаг (англ.... Posted: 21 Apr 2021 09:52 AM PDT |
| forma-odezhda.ru Archive: 21 Tweets - 6,384 Impressions Posted: 21 Apr 2021 09:48 AM PDT This is a snapshot archive. It will not be updated. With a subscription, we will pull as many as 2000 of the latest tweets and then update the archive hourly. |
| Posted: 21 Apr 2021 09:47 AM PDT Don't have Telegram yet? Try it now! External link: forma video t.me  Article: forma video (Analogindex.com) |
| Posted: 21 Apr 2021 09:39 AM PDT 13.09.2020 — SYN: breast. SEE ALSO: mammary gland. [L.] m. accessoria [TA] SYN: accessory breast. m. erratica a supernumerary breast aberrantly located, i.e., in some part ... |
| Posted: 21 Apr 2021 09:44 AM PDT Enacademic https://ift.tt/3v85HyL |
| Is forma-odezhda.ru Safe? forma-odezhda Reviews & Safety ... Posted: 21 Apr 2021 09:48 AM PDT Ratings and Reviews for forma-odezhda - WOT Scorecard provides customer service reviews for forma-odezhda.ru. Use MyWOT to run safety checks on any website. |
| https://t.me/enacademicgroup/5355438 Posted: 21 Apr 2021 09:37 AM PDT العربية: feedspot (RSS) -- Delivered by Feed43 service |
| Posted: 21 Apr 2021 09:44 AM PDT https://apescout.com/site/translate.academic2.ru WebSite Statistics & InformationTranslate.Academic2.Ru WebSite Stats | ApeScout.ComFree WebSite Statistics & Informatinos about any website. This posting includes an audio/video/photo media file: Download Now |
| Posted: 21 Apr 2021 09:38 AM PDT (https://clck.ru/PWzqK)together (RSS) Telegram pub (RSS) Detected change on https://clck.ru/PWzqK This is a change monitoring for... (https://t.me/enacademic/2281722) (https://clck.ru/PWzqK)Telegram pub (RSS) Detected change on https://clck.ru/PWzqK (https://clck.ru/PWzqK?diffydate=1618994828) This is a change monitoring for https://clck.ru/PWzqK delivered by deltaFeed Сообщений за сутки: youtube.comcomment : 548426 twitter.com (http://twitter.com/) : 282903 twitter.comcomment : 257453 vk.com (http://vk.com/) : 132572 vk.comcomment : 47766 mail.ru (http://mail.ru/) : 10831 livejournal.com (http://livejournal.com/) : 9806 youtube.com (http://youtube.com/) : 4539 livejournal.comcomment : 3048 ok.ru (http://ok.ru/) : 2554... View original post (https://t.me/enacademic/2281722) |
| Vista Realty Partners Names New Regional Partners Posted: 21 Apr 2021 09:45 AM PDT ATLANTA, April 21, 2021 /PRNewswire/ -- Vista Realty Partners ("VISTA"), the leading Atlanta-based real estate investment company, has appointed two regional partners to its expanding leadership team. The announcement marks the first phase of the group's Southeast expansion plan, with additional regions on the horizon. Brett Gelsomino, formerly of ZOM, has partnered with VISTA founder & CEO Eduard de Guardiola, to open a new office in Florida. Gelsomino will oversee all operations of VISTA's new Florida office, including site selection, design, financing, development and construction management, asset management, and ultimately disposition throughout the State. Throughout his career, Brett has developed over 2,500 multifamily and senior living units across multiple markets, at a cost value of over $1 billion. "VISTA is fortunate to bring on as a new regional partner for Florida, someone as experienced and knowledgeable about the Florida multifamily market as Brett Gelsomino. Brett's expertise will position VISTA to quickly establish itself as a successful development firm in this fast-growing State." Eduard de Guardiola, Founder & CEO of Vista Realty Partners. Michael Neyhart, former Director of Investments at VISTA has been promoted to Managing Director & Regional Partner. In his new role, Neyhart will oversee all operations of VISTA'S Multi-Family platform in the Atlanta office. Michael's responsibilities will include site selection, architectural and engineering design, development, construction management, finance, asset management and disposition throughout the Georgia & Alabama region. During his tenure at VISTA, Michael has played a central role in the acquisition and development of over 4,500 units, with a total capitalization exceeding $600 million. "For the past eight years, Michael has worked side-by-side with me as we have successfully executed over 20 multi-family projects in Atlanta. He is a proven and skilled developer, rightly poised to assume his new leadership role." - Eduard de Guardiola About VistaFounded in 2000, Vista is an Atlanta-based real estate investment company specializing in the operation and development of rental and for-sale multifamily housing throughout the Southeast. Vista's portfolio includes over 60 properties, totaling almost 13,000 units and over $1.4 billion in value. The company is currently focused on ground-up developments, but has extensive experience in acquiring assets at discounts to replacement that offer the opportunity to increase yields through the execution of a value-creation strategy. For additional information visit www.vistarp.com Contact: Jessica Adams Phone:561.317.7512 Email: jessica@jsquaredgrp.com View original content to download multimedia: http://www.prnewswire.com/news-releases/vista-realty-partners-names-new-regional-partners-301274076.html SOURCE Vista Realty Partners |
| Here's Android 12 Developer Preview 3! Posted: 21 Apr 2021 09:59 AM PDT  Google has just released Android 12 Developer Preview 3, which should be the last developer preview for Android 12. Next month, we should be getting our first beta. Which should also coincide with Google I/O, which is set for May 18-20. Like the previous developer previews, this one will be available on the Pixel 3 and later. And you'll also have to sideload or flash the preview onto your Pixel device. As the Beta Program for Android 12 is not yet open, so there's no OTA's just yet. But that is expected to change next month with the first beta for Android 12. You can download the third developer preview from Google here. And sideload the OTA from here. If you need help flashing the factory image or sideloading the OTA onto your Pixel device, you can check out this tutorial here. What's new in this developer preview?Since this is still a developer preview and not a beta, the majority of these changes are still developer facing changes. However, there are still a few changes for Android 12 in this developer preview. Google is expanding the haptic experiences in Android 12. Developers will be able to use new haptic feedback to emphasize key events and actions in the UI. Google has also improved app links. With this latest preview, it brings a frictionless linking experience. Allowing developers to get users clicking on a link they own into their app faster. The last big change is in regards to app launch animations. Google wanted to give the app startup experience a bit more consistency. So in Android 12 Developer Preview 3, there is a new launch experience. Where developers can customize to fit their app branding and design. There will likely be some other changes found in this preview, but these are the major ones that Google is talking about in its press release. The post Here's Android 12 Developer Preview 3! appeared first on Android Headlines. |
| "Юрка вернулся!" Возвращение Юрия Никулина с фронта. 1946 год Posted: 21 Apr 2021 10:07 AM PDT |
| academic2.ru united (RSS) Еще работаем oligodactyly Перевод: с... Posted: 21 Apr 2021 09:52 AM PDT |
| Cultiva® Enhances Global Leadership Team Posted: 21 Apr 2021 09:47 AM PDT LAS VEGAS, April 21, 2021 /PRNewswire/ -- Cultiva LLC ( cultiva.com), a provider of proprietary, food-grade biofilms used in agricultural markets, announces the appointment of Cleiton De Sequeira as director, Global Strategic Marketing - a new role at Cultiva as the company sets the stage for future growth. De Sequeira will lead the company's marketing vision, brand identity and execution in his new role as a part of Cultiva's leadership team. His responsibilities include building the global Cultiva brand by showcasing the company's leadership in pre-harvest crop protection technologies. As Cultiva leverages its steep growth curve, De Sequeira will drive worldwide market development, marketing strategy, positioning and messaging around proprietary emerging technologies and innovations in existing and new markets. "Adding Cleiton's expertise to our executive team affirms our focus on growth and innovation," said Luis Hernandez, CEO of Cultiva. "His experience and knowledge will help us build Cultiva's presence in new markets, and leverage our proprietary SureSeal™ technology as we scale in the U.S. and internationally." Most recently, De Sequeira was with international mining and metals company Rio Tinto, where he served as Global Market Development Manager for the company's agriculture business. Prior to that, he held roles in agronomy and sales at Koch Industries in Buenos Aires, Argentina, and Wichita, Kansas. "Cultiva has a unique technology advantage helping farmers improve quality and value," De Sequeira said. "They're positioned to make big leaps in the market. I'm looking forward to building the Cultiva brand on a global scale." De Sequeira has a Ph.D. in crop and soil environmental sciences from Virginia Tech, and was a post-doctoral research associate at the University of Nebraska, Lincoln. In addition, he holds an MBA from Austral University's IAE Business School in Pilar, Buenos Aires, and a Bachelor of Sciences degree in Agronomy from Universidade Federal de Viçosa, Minas Gerais, Brazil. About Cultiva ® Cultiva has developed a proprietary technology called SureSeal™ designed to supplement the cuticle of the plant. By enhancing the plant's membrane stability, the company's products reduce crop losses associated with environmental extremes that have become more prevalent with climate change. Cultiva's vision is to stay at the forefront of plant cuticle care by continuing to explore the capabilities of this technology and develop new applications that provide agronomic value to growers worldwide. Contact: Stacy Einck Axiom Marketing (952) 224-2939, X113 seinck@axiomcom.com View original content to download multimedia: http://www.prnewswire.com/news-releases/cultiva-enhances-global-leadership-team-301274078.html SOURCE Cultiva |
| DLA Piper Advises Ekata In Its US$850 Million Acquisition By Mastercard Posted: 21 Apr 2021 09:44 AM PDT DLA Piper Advises Ekata In Its US$850 Million Acquisition By Mastercard https://ift.tt/3dIepOF |
| Oppenheim sign - Medical dictionary - Enacademic.com Posted: 21 Apr 2021 09:39 AM PDT 16.01.2021 — Look at other dictionaries: Oppenheim's sign — is dorsiflexion of the big toe elicited by irritation downward of the medial side of the tibia[1] Positive sign indicates ... |
| Statement On Issuance Of Form FDA 483 At Emergent Bayview Facility Posted: 21 Apr 2021 09:46 AM PDT GAITHERSBURG, Md., April 21, 2021 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) has completed its inspection of Emergent BioSolutions' (EBS) - Get Report Baltimore-Bayview facility and provided specific feedback. Given the heightened focus on this facility, the FDA has proactively shared its findings to keep the public, policymakers and all other stakeholders informed. The issuance of findings by the FDA is normal following a facility inspection and provides direction on the necessary steps to improve operations. Emergent is committed to working with the FDA and Johnson & Johnson to quickly resolve the issues identified. We deeply value the relationship we have with our manufacturing partners and with the FDA. The FDA's feedback will help us continue to improve and strengthen the supply chain for Johnson & Johnson's COVID-19 vaccine. While we are never satisfied to see shortcomings in our manufacturing facilities or process, they are correctable and we will take swift action to remedy them. We are exceedingly proud of our heroic workforce in Baltimore who have stepped up to work 24/7 to ensure vaccines will be produced with the highest quality and be quickly available to fight this pandemic. About Emergent BioSolutionsEmergent BioSolutions is a global life sciences company whose mission is to protect and enhance life. Through Emergent's specialty products and contract development and manufacturing services, Emergent is dedicated to providing solutions that address public health threats. Through social responsibility, Emergent aims to build healthier and safer communities. Emergent aspires to deliver peace of mind to its patients and customers so they can focus on what's most important in their lives. In working together, Emergent envisions protecting or enhancing 1 billion lives by 2030. For additional information, visit Emergent's website and follow Emergent on LinkedIn , Twitter and Instagram . Safe Harbor StatementThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact, including statements regarding our supply chain and resolution of the issues identified and any other statements containing the words "believes," "expects," "anticipates," "intends," "plans," "estimates" and similar expressions, are forward-looking statements. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. The reader should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances. There are a number of important factors that could cause the company's actual results to differ materially from those indicated by such forward-looking statements. The reader should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the SEC, when evaluating our forward-looking statements. Media Contact:Matt HartwigDirector, Media RelationsHartwigM@ebsi.com Investor Contact:Robert G. BurrowsVice President, Investor RelationsBurrowsR@ebsi.com |
| https://t.me/enacademicgroup/5355426 Posted: 21 Apr 2021 09:37 AM PDT Русский: вместе (RSS) -- Delivered by Feed43 service |
| https://t.me/enacademicgroup/5355430 Posted: 21 Apr 2021 09:37 AM PDT top 30 -- Delivered by Feed43 service |
| http://www.seomastering.com/audit/translate.academic2.ru/ Posted: 21 Apr 2021 09:42 AM PDT
|
| Posted: 21 Apr 2021 09:48 AM PDT Law Offices of Howard G. Smith reminds investors of the upcoming June 11, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired FibroGen Inc. ("FibroGen" or the "Company") (FGEN) - Get Report securities between November 8, 2019 and April 6, 2021, inclusive (the "Class Period"). Investors suffering losses on their FibroGen investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com. FibroGen is a biopharmaceutical company that develops medicines for the treatment of anemia, fibrotic disease, and cancer. Its most advanced product is roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor-prolyl hydroxylase ("HIF-PH") activity that acts by stimulating the body's natural pathway for red cell production. In December 2019, the Company filed its New Drug Application ("NDA") with the U.S. Food and Drug Administration ("FDA") for the approval of roxadustat for the treatment of anemia due to chronic kidney disease ("CKD"). On April 6, 2021, after the market closed, FibroGen issued a statement "provid[ing] clarification of certain prior disclosures of U.S. primary cardiovascular safety analyses from the roxadustat Phase 3 program for the treatment of anemia of chronic kidney disease ('CKD')." Specifically, the Company stated that the safety analyses "included post-hoc changes to the stratification factors." FibroGen further revealed that, based on analyses using the pre-specified stratification factors, the Company "cannot conclude that roxadustat reduces the risk of (or is superior to) MACE+ in dialysis, and MACE and MACE+ in incident dialysis compared to epoetin-alfa." On this news, the Company's share price fell $14.90, or 43%, to close at $19.74 per share on April 7, 2021, on unusually heavy trading volume. The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that certain safety analyses submitted in connection with FibroGen's NDA for roxudustat included post-hoc changes to stratification factors; (2) that, based on analyses using the pre-specified stratification factors, the Company could not conclude that roxadustat reduces the risk of major adverse cardiovascular events compared to epoetin-alfa; (3) that, as a result, the Company faced significant uncertainty that its NDA for roxadustat as a treatment for anemia of CKD would be approved by the FDA; and (4) as a result, Defendants' statements about its business, operations, and prospects were materially false and misleading and/or lacked reasonable basis at all relevant times. If you purchased or otherwise acquired FibroGen securities during the Class Period, you may move the Court no later than June 11, 2021to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005863/en/ |
| deacademic.com Kultus 01.03.2021 — ist die Bezeichnung für eine Verwaltungsbehörde... Posted: 21 Apr 2021 09:44 AM PDT deacademic.com Kultus 01.03.2021 — ist die Bezeichnung für eine Verwaltungsbehörde... https://ift.tt/3n74gxT |
| InventHelp Inventor Develops Child Safety System For Vehicles (ORD-2884) Posted: 21 Apr 2021 09:45 AM PDT PITTSBURGH, April 21, 2021 /PRNewswire/ -- "I wanted to create a system to prevent parents from leaving a child unattended in a parked car," said an inventor, from Kissimmee, Fla., "so I invented the B O B DEVICE. My design could help to prevent heat- or cold-related injuries associated with being left in a parked car." The patent-pending invention provides an effective reminder to remove a child from a vehicle upon parking. In doing so, it prevents the child or pet from being accidentally left behind. As a result, it enhances safety and it provides added peace of mind. The invention features a user-friendly design that is convenient and easy to use so it is ideal for parents with young children and pet owners. Additionally, it is producible in design variations. The original design was submitted to the Orlando sales office of InventHelp. It is currently available for licensing or sale to manufacturers or marketers. For more information, write Dept. 19-ORD-2884, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext. 1368. Learn more about InventHelp's Invention Submission Services at http://www.InventHelp.com. View original content to download multimedia: http://www.prnewswire.com/news-releases/inventhelp-inventor-develops-child-safety-system-for-vehicles-ord-2884-301273569.html SOURCE InventHelp |
| Posted: 21 Apr 2021 09:58 AM PDT |
| https://apescout.com/site/translate.academic2.ru Posted: 21 Apr 2021 09:44 AM PDT
|
| Posted: 21 Apr 2021 09:44 AM PDT Nancy Ludington https://ift.tt/2ROJDuJ |
| forma-odezhda.ru - searX.Slash-dev.de Posted: 21 Apr 2021 09:48 AM PDT searx - a privacy-respecting, hackable metasearch engine. Search URL. Download results |
| Posted: 21 Apr 2021 09:49 AM PDT Law Offices of Howard G. Smith reminds investors of the upcoming June 15, 2021deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased LifeMD, Inc. ("LifeMD" or the "Company") (LFMD) securities between January 19, 2021 and April 13, 2021, inclusive (the "Class Period"). Investors suffering losses on their LifeMD investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com. On April 14, 2021, Culper Research issued a report alleging that "LifeMD appears to use unlicensed doctors to dispense OTC medications, has implemented an autoshipping/autobilling scheme, failed to honor guarantees, and put in place abusive telemarketing practices." The report also alleged that several of the Company's executives were involved in "wide ranging fraud" at Redwood Scientific, which was charged by the U.S. Federal Trade Commission for "unlawful autoshipping, abusive telemarketing, and false claims." Specifically, according to Culper Research, "many customers are effectively duped into purchasing subscriptions rather than one-time purchases" and LifeMD "makes cancellations difficult if not impossible." On this news, the Company's share price fell $2.84, or 24%, to close at $9.00 per share on April 14, 2021, on unusually heavy trading volume. Throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that many of LifeMD's executives were associated with Redwood Scientific when it was charged for unlawful autoshipping, abusive telemarketing, and false claims, and that they employed similar practices at the Company; (2) that LifeMD engaged in autoshipping products to unwilling customers to record recurring revenue and the Company made it difficult to cancel such subscriptions; (3) that certain of the purportedly licensed physicians on the Company's platform were not in fact licensed and faced disciplinary action; (4) that, as a result of the foregoing practices, the Company was reasonably likely to face regulatory scrutiny and/or reputational harm; and (5) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. If you purchased or otherwise acquired LifeMD securities during the Class Period, you may move the Court no later than June 15, 2021to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210421005865/en/ |
| Detected change on https://clck. Posted: 21 Apr 2021 09:38 AM PDT together (RSS) Telegram pub (RSS) Detected change on https://clck.ru/PWzqK This is a... https://t.me/enacademic/2282032 |
| https://t.me/enacademicgroup/5355428 Posted: 21 Apr 2021 09:37 AM PDT Русский: вместе (RSS) -- Delivered by Feed43 service |
| полный дайджест (RSS) Forma-odezhda. Posted: 21 Apr 2021 09:40 AM PDT Русский: feedspot (RSS) полный дайджест (RSS) Forma-odezhda.ru (VK) У вас еще нет Telegram? Попробовать это... https://t.me/enacademic/2282035 feedspot (RSS) полный дайджест (RSS) Forma-odezhda.ru (http://forma-odezhda.ru/) (VK) У вас еще нет Telegram? Попробуйте это сейчас! ... полный дайджест (RSS) Forma-odezhda.ru (http://forma-odezhda.ru/) (ВКОНТАКТЕ) Телеграммы еще нет? Попробуйте прямо сейчас! Телеграммы еще нет? Попробуйте прямо сейчас! Контекст Встроить Просмотр В Канале Копировать TelegramEnacademic |
| (https://clck.ru/PWzqK)together (RSS) Telegram pub (RSS) Detected change on... Posted: 21 Apr 2021 09:38 AM PDT |
| Valve исправила ошибку, из-за которой страдали пользователи Steam более чем с 25 тыс. игр Posted: 21 Apr 2021 09:51 AM PDT В настоящее время в Steam продаётся свыше 51 тыс. игр. Но оказалось, что до недавнего времени приложение сервиса не справлялось с библиотекой пользователей, которая превышала 25 тыс. наименований. Последнее обновление бета-клиента Steam исправило недочёт, из-за которого случалось аварийное завершение работы приложения у пользователей с более 25 тыс. игр в библиотеке. Как отметили на Reddit, это может означать, что кто-то, кто в настоящее время владеет такой обширной коллекцией, заметил проблему и доложил о ней Valve. |
| You are subscribed to email updates from together. To stop receiving these emails, you may unsubscribe now. | Email delivery powered by Google |
| Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States | |
Комментариев нет:
Отправить комментарий